Integrated histopathology-transcriptomic biomarker enhances survival prediction in HNSCC patients treated with immunotherapy.

Transl Oncol · 2026 · PMC13226123 · PMID 42176558

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the Pembro cohort, patients classified as low-risk (n = 17) showed a trend toward better PFS outcomes compared to those classified as high-risk (n = 15), with a log-rank p-value of 0.147.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.